What is the stool softener of choice for an infant with constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Stool Softener of Choice for Infant Constipation

Polyethylene glycol (PEG) is the stool softener of choice for infant constipation due to its superior efficacy, safety profile, and evidence supporting its use in infants. 1

First-Line Treatment Options

  • PEG (polyethylene glycol) is the most effective laxative for both disimpaction and maintenance therapy in infants with constipation, with a recommended maintenance dose of approximately 0.78 g/kg/day 1
  • PEG has been shown to be safe and effective in infants younger than 18 months, with a 97.6% success rate in relieving constipation 1
  • For infants with constipation, formulas enriched with high β-palmitate and increased magnesium content may be considered to soften stool if the infant is formula-fed 2

Evidence Supporting PEG Use

  • PEG has demonstrated superiority over placebo with significantly increased number of stools per week (mean difference 2.61 stools per week) 3
  • PEG is more effective than lactulose in increasing stool frequency (mean difference 0.70 stools per week) and reduces the need for additional laxative therapies 3
  • PEG is also superior to milk of magnesia in increasing stool frequency (mean difference 0.69 stools per week) 3
  • Dose determination studies show that PEG at approximately 0.50 g/day/kg is effective in more than 90% of constipated children 4

Why Not Docusate?

  • Docusate sodium (a common stool softener) lacks experimental evidence supporting its use in constipation management 5
  • Guidelines explicitly state that docusate has not shown benefit and is therefore not recommended for constipation management 5
  • Despite being marketed as a stool softener 6, docusate is listed under "Laxatives generally not recommended" in clinical guidelines 5

Treatment Algorithm for Infant Constipation

  1. Initial management:

    • For breastfed infants with constipation, continue breastfeeding and do not transition to formula 2
    • For formula-fed infants, consider PEG at an initial dose of 0.88 g/kg/day (range 0.26-2.14 g/kg/day) 1
  2. Maintenance therapy:

    • Adjust PEG dose to approximately 0.78 g/kg/day (range 0.26-1.26 g/kg/day) 1
    • Continue maintenance treatment for at least 2 months 7
  3. If PEG is unavailable or poorly tolerated:

    • Lactulose is the preferred alternative, though less effective than PEG 7, 3
    • Liquid paraffin (mineral oil) has shown efficacy compared to lactulose (mean difference 4.94 stools per week) but should be used with caution in infants due to risk of aspiration 3

Monitoring and Adverse Effects

  • Common adverse events with PEG include transient diarrhea (resolves with dose adjustment) and increased gas 1
  • Monitor for normal bowel movements (goal is one non-forced bowel movement every 1-2 days) 8
  • Reassess if constipation persists despite adequate therapy to rule out underlying conditions 8

Important Considerations and Pitfalls

  • Avoid bulk-forming laxatives like psyllium (Metamucil) as they are unlikely to control constipation effectively 8
  • Ensure adequate fluid intake alongside laxative therapy 8
  • Early treatment results in faster resolution and shorter treatment course 7
  • Do not discontinue breastfeeding in favor of formula feeding for constipation management 2

References

Research

Polyethylene glycol for constipation in children younger than eighteen months old.

Journal of pediatric gastroenterology and nutrition, 2004

Research

Osmotic and stimulant laxatives for the management of childhood constipation.

The Cochrane database of systematic reviews, 2016

Guideline

Constipation Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

adult cancer pain.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Related Questions

Can lactulose be given to a 1.5-month-old infant?
Is milk of magnesia (magnesium hydroxide) safe for a constipated 2-year-old child and what is the recommended dose?
What are the AAP guidelines for using Miralax (polyethylene glycol) versus glycerin suppository in a 5-month-old infant with constipation?
Should I be concerned or just continue monitoring a 2.5‑year‑old child who has not had a bowel movement since Wednesday, is receiving 8 g polyethylene glycol (Miralax) daily, is still passing gas, drinks about two sippy‑cup servings daily, and wets every diaper?
In an 11.7‑kg child being treated with polyethylene glycol 3350 (Restoralax) 11.1 g twice daily for nine days for constipation, who continues to pass mixed stools with hard dark pellets, intermittent abdominal distension, low appetite, and no vomiting, should the current clean‑out dose be continued, how can we determine when complete stool clearance has been achieved, and when should we transition to a maintenance regimen or consider escalation such as imaging or alternative clean‑out methods?
How to rule out the possibility of a leak and fistula formation in a patient with a surgical site infection after colostomy closure?
What are the risk factors for silent miscarriage?
What are the key parameters for diagnosing and treating Hemophagocytic Lymphohistiocytosis (HLH)?
What are the treatment options for renal artery aneurysm?
What are the best binding agents for gastrointestinal potassium loss?
Should verapamil be held in patients with Chronic Kidney Disease (CKD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.